Thazha P Prakash

This inventor holds 89 USPTO granted patents and 72 published patent applications, plus 8 CIPO patents and 46 EPO patents, primarily in Gene Modulation (CPC class C12N15-113). Top assignees: Isis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., The University of Texas System. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thazha P Prakash. Retrieved from https://idiyas.com/inventor/thazha-p-prakash

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 89 (Patent Applications = 72)

% Patents Active = 88.8

CIPO Patents = 8 (Patent Applications = 23)

EPO Patents = 46 (Patent Applications = 77)

Average Co-Inventor Count = 4.1

ph-index = 23

Forward Citations = 3,040(Granted Patents)

Forward Citations (Not Self Cited) = 2,729(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Company Filing History:

43 out of 1,035

Isis Pharmaceuticals, Inc.

patents

42 out of 289

Ionis Pharmaceuticals, Inc.

patents

3 out of 5,644

The University of Texas System

patents

4. 2 out of 47

Academisch Ziekenhuis Leiden

patents

5. 2 out of 466

Alnylam Pharmaceuticals, Inc.

Alaylam Pharmacueuticals, Inc.

Lonis Pharmaceuticals, Inc.

patents

10. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

11. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

Gene Modulation

Apolipoprotein C-III

TTR Expression

CRISPR RNA

Oligonucleotides

Antisense Compounds

Growth Hormone Receptor

Complement Factor B

Frataxin Expression

Angiopoietin-like 3

Nucleosides

Reactive Conjugate Clusters

89 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516319 - COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION (2026-01-06),

2. 12509684 - COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION (2025-12-30),

3. 12291709 - Compositions and methods for modulating apolipoprotein (a) expression (2025-05-06),

4. 12115225 - GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof (2024-10-15),

5. 11851655 - Compositions and methods for modulating apolipoprotein (a) expression (2023-12-26),

6. 11732265 - Compositions and methods for modulating complement factor B expression (2023-08-22),

7. 11459564 - Modulation of frataxin expression (2022-10-04),

8. 11414657 - Modified CRISPR RNA and modified single CRISPR RNA and uses thereof (2022-08-16),

9. 11312964 - Compositions and methods for modulating growth hormone receptor expression (2022-04-26),

10. 11299736 - Conjugated antisense compounds and their use (2022-04-12),

11. 11293025 - Compositions and methods for modulating Ataxin 3 expression (2022-04-05),

12. 11268094 - 5' modified nucleosides and oligomeric compounds prepared therefrom (2022-03-08),

13. 11260073 - Compounds and methods for modulating C90RF72 (2022-03-01),

14. 11104899 - Oligomer-conjugate complexes and their use (2021-08-31),

15. 11084844 - Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom (2021-08-10),

Title: Innovator Spotlight: Thazha P Prakash

Introduction: Thazha P Prakash is a prolific inventor based in Carlsbad, CA, with a remarkable portfolio consisting of 86 patents. His contributions to the field of biotechnology, particularly in the area of oligonucleotide therapeutics, have made significant impacts on medical science.

Latest Patents: Among his latest innovations are two significant patents. The first patent, titled "GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof," provides compounds and methods for targeting cells that express the GLP-1 receptor. This innovation aims to advance therapeutic approaches in treating conditions related to these receptors. The second patent, "Compositions and methods for modulating apolipoprotein (a) expression," discusses oligomeric compounds designed to target apolipoprotein (a) [apo(a)]. These compounds are conjugated with N-Acetylgalactosamine and are intended for use in treating diseases related to apo(a) and Lp(a), including inflammatory, cardiovascular, and metabolic conditions.

Career Highlights: Thazha P Prakash has had a successful career, having worked with leading companies in the biotechnology field. He spent significant time at Isis Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., both renowned for their cutting-edge research and development in genetic medications.

Collaborations: Throughout his career, Prakash has collaborated with talented professionals such as Eric E Swayze and Punit P Seth. These collaborations have undoubtedly enriched his work and contributed to the innovative solutions he continues to develop.

Conclusion: Thazha P Prakash exemplifies the spirit of innovation in the biotechnology sector with his extensive patent portfolio and impactful collaborations. His dedication to advancing therapeutic techniques promises to pave the way for new treatments and improvements in health care.

Profile summary based on public USPTO records.